A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
{ "Phase 2 Study of HLX-1502 for Neurofibromatosis Type 1", "This Phase 2 study is testing a drug called HLX-1502 for people with Neurofibromatosis Type 1 (NF1). The study aims to see how safe HLX-1502 is and how well it works to shrink or improve plexiform neurofibromas (PNs), which are tumors that can grow in NF1. You might be able to join if you are 12 years or older, have NF1, and have PNs that are growing or causing problems. The study will look at how many participants' PNs respond to the treatment after 12 months. This study is currently recruiting, but the exact status is unclear.", "design": "This is an open-label, single-arm, Phase 2 study involving about 25 participants. Everyone in the study will receive the drug HLX-1502.", "commitments": "Participants will take HLX-1502 by mouth three times a day for up to 24 cycles, with each cycle lasting 28 days.", "compensation": "Not stated in the trial record.", "follow_up": "The main measure of success will be checked at 12 months, but the total follow-up duration is not specified.", }
- Study design
- Not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
At a glance
Conditions
Where it's being run
14 sites across 12 statesStudy leadership
- Miriam Bornhorst · STUDY_CHAIR · Lurie's Children's Hospital
- Michael Fisher · STUDY_CHAIR · Children's Hospital of Philadelphia
- Kathryn Nevel · STUDY_CHAIR · Indiana University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- PN response rate12 months
Response will be determined by a blinded centralized review of volumetric MRI. A partial response (PR) is defined as ≥ 20% decrease in the volume of target PN.